



Effect of progesterone and first evidence about allopregnanolone action on the 
progression of epithelial human ovarian cancer cell lines.  
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Abstract 
Introduction: Ovarian carcinoma is one of the most common cause of death by 
gynecologic cancer. Several epidemiologic and in vitro studies have shown 
controversial data about progesterone effects in ovarian cancer. Progesterone can be 
converted in its active metabolite, allopregnanolone, its effects in ovarian cancer are 
still unkown. Previously, we demonstrated that allopregnanolone modifies ovarian 
morphophysiology, being able to alter critical process of tumor development such as 
proliferation, apoptosis and angiogenesis. Taking into account these antecedents, we 
investigated the effect of progesterone and allopregnanolone on proliferation, 
apoptosis, clonogenic capacity and migration on two epithelial human ovarian cancer 
cell lines, IGROV-1 and SKOV-3. 
Materials and methods: IGROV-1 and SKOV-3 cells were exposed to a range of 
progesterone and allopregnanolone concentrations (10-11 to 10-5 M) for 72 h. 
Proliferation was analyzed by MTT and Ki67 expression. Apoptosis was measured by 
immunocytochemistry of cleaved caspase 3. Clonogenic capacity was evaluated by 





Results: We showed that allopregnanolone increased proliferation in a concentration 
dependent manner with respect to control on IGROV-1 and it also enhanced Ki67 
expression. Expression of cleaved caspase 3 did not change in any cell line studied. 
IGROV-1 clonogenic capacity was also increased by allopregnanolone treatment. Both 
steroids, progesterone and allopregnanolone, increased IGROV-1 migration in a 
concentration dependent manner. Interestingly none of the steroids tested modified 
SKOV-3 progression steps.  
Conclusion: This is the first evidence that allopregnanolone, a progesterone 
metabolite, affects tumor progression of human epithelial ovarian cancer. These results 
could have an impact in the future in clinic diagnosis, prognosis and treatment of 
ovarian cancer patients. The regulation of progesterone and allopregnanolone 




Ovarian cancer is the most lethal form of gynecological neoplasia and the fifth leading 
cause of death in women´s cancer.  Approximately, 80-90% of ovarian tumors present 
an epithelial origin and are usually diagnosed in metastatic stages with poor survival 
rates. They are highly heterogeneous and can be classified according to histological 
subtypes: high- and low-grade serous, clear cell, endometroid, mucinous and 
undifferenciated cells. Each of these subtypes are associated with different responses 
to chemotherapy, patterns of metastasis and survival.  Surgery and chemotherapy 
based in paclitaxel or carboplatin have been the standard therapies since past two 
decades. At this moment, epidemiological and in vitro evidences on progesterone (P4)  
in ovarian cancer are controversial, which may explain why clinical studies have not 
shown improvement in patients [1-3]. Examples of this are, an increased incidence of 
ovarian cancer in women with progesterone defiency, while overexpression of P4 
receptor is associated with a worse recurrence-free survival and augmented P4 serum 
levels in smoking patients are related with a poor prognosis [ 4, 5]. In addition, there 
are many in vitro studies where P4 binds to different receptors associated with anti-
apoptotic or pro-apoptotic pathways [6-9]. Therefore, it is necessary to clarify its 
function and mechanism. 
In breast cancer, P4 derivatives could have anti-tumor (4-pregnenes) or pro-tumor (5α-
pregnanes) effects [10]. P4 is converted directly into the derivatives 4-pregnanes and 




reductase. Then, 5α-DHP could be converted, in a reversible manner, in 
allopregnanolone (ALLO, 3α-hydroxy-5α-pregnan-20-one or 3α-5α-
tetrahydroprogesterone) by the 3α-hydroxysteroid oxido-reductase (3α-HSOR). 
Tumorigenic breast tissues and breast cancer cell lines have higher concentration of 
5α-DHP than normal ones [11]. Besides, 5α-DHP stimulates the proliferation in breast 
cancer lines [12]. 
ALLO has been mostly studied in the central nervous system (CNS), as an active 
derivative of progesterone. However, ALLO is synthesized in the CNS, as well as in the 
peripheral glands (adrenal and ovary). Previous studies demonstrated that ALLO 
increases in situations of acute stress and generates negative mood changes related to 
menstruation and menopause [13, 14]. In fact, it is known that the concentration of 
ALLO and P4 varies during the estrous cycle and pregnancy in a similar manner. We 
have reported that intra-cerebroventricular (ICV) administration of ALLO modulates the 
hypothalamic-pituitary-gonadal axis and induces morpho-physiological changes at the 
ovarian level [15-18]. ALLO induces a reduction in nuclear proliferation cell antigen 
expression, accompanied by an increase in apoptosis of granulosa cells stimulating 
follicular atresia. On the other hand, ALLO increases the number of old corpora lutea 
with an inhibition of apoptosis and an increase in angiogenesis [19]. These alterations 
in follicles and corpora lutea led us to hypothesize that ALLO may also be involved in 
carcinogenesis, where proliferation, apoptosis and angiogenesis play a critical role [20, 
21]. 
 
Taking into account the previous findings, it is important to elucidate the role of ALLO in 
ovarian cancer, which is still unknown.  We hypothesize that P4 and/ or its active 
metabolite (ALLO) can affect tumor progression. The purpose of this study was to 
analyze the effect of P4 and ALLO on proliferation, apoptosis, clonogenic capacity and 
migration on epithelial cell lines of ovarian cancer. Here we provide the first evidence 
that ALLO is involved in ovarian cancer progression.  
 
2. Materials and methods 
2.1. Cell Culture 
The human ovarian carcinoma cell lines IGROV-1 and SKOV-3 were purchased from 
the American Type Culture Collection (ATCC; Manassas, USA), IGROV-1 is sensitive 
to cis-platinum treatment; histological diagnosis was of an ovarian epithelioma with 
multiple differentiations, endometroid, with some serous clear cells and undifferentiated 




an ovarian serous carcinoma [23].  Both cell lines were cultured in RPMI medium 
(Invitrogen Inc., Carlsbad, CA, USA) with 2 mM L-glutamine, 80 μg/ml gentamicin, 50 
UI/ml penicilin supplemented with 10% fetal bovine serum (FBS; Internegocios, 
Argentina) at 37°C in a humidified 5% CO2 air.  
Cell lines were detached using 0.25% trypsin and 0.02% EDTA in Ca2+ and Mg2+ free 
phosphate buffer saline (PBS) in sub confluent monolayers. The medium was replaced 
three times a week. Cell viability was assayed by Trypan blue exclusion test, and the 
absence of mycoplasma was confirmed by Hoechst staining. 
 
2.2. Cell Proliferation Assay 
Growth in vitro studies were conducted using the soluble tetrazolium salt MTS 
colorimetric assay (Cell Titer 96TM AQueous Non-Radioactive Cell Proliferation Assay, 
Promega, Madison, WI, USA). MTS couples fenazine methylsulfate (PMS) and is 
reduced to formazan. Both cell lines were seeded in 96-well microplates at a density of 
5000 cells per well in RPMI medium supplemented with 5% FBS. After 24h, cells were 
deprived of FBS to induce quiescence  (24 h previous to the proliferation assay) and 
were treated with increasing concentrations of P4 or ALLO (10-11-10-5 M)  by 
sextuplicate during 72 h. Later, the medium was replaced with 100 μl of fresh medium 
containing 20 μl MTS: PMS (20: 1), and after 2 h of incubation at 37°C, the production 
of formazan was evaluated by measuring the absorbance at 490 nm with an ELISA 
reader (Bio-Rad Laboratories, Inc. Oakland, CA, USA). Three independent experiment 
were made; and the mean absorbance value of the sextuplicate samples ± SEM were 
calculated for each experiment. Results were expressed as a percentage of stimulation 
in relation to control (cells without treatment). Moreover, alive and dead cells were 
analyzed through direct cell count with trypan blue [25]. 
 
2.3. Immunocytochemistry  
Cells were growing cultured on glass coverslips, treated and fixed in 4 % formaldehyde 
for 15 min and permeabilized with 0.5 % Triton X-100 for 5 min as described by Cuello-
Carion et al. 2015 [26]. Fixed cells were incubated with the primary antibodies 
overnight at 4 °C in humidity chambers; we use a monoclonal mouse anti KI67 
antibody (DAKO, Carpinteria, CA, USA; 1:100); and a rabbit polyclonal antibody 
against Caspase 3 (Abcam, ABCAM, Cambridge, Reino Unido; 1:400). A commercial 
kit to detect mouse and rabbit primary antibodies was used [Dako EnVision System, 
horse radish peroxidase, diaminobenzidine (DAB), from Dako, Carpinteria, CA, USA]. 




and photographed with a Nikon Eclipse E200 microscope (Japan). Non-specific mouse 
IgG1 antibody and purified rabbit pre-immune serum (DAKO, Kingsgrove, NSW, 
Australia) were used as isotype negative controls.  The percentage of proliferative or 
apoptotic cells was determined by counting  200 cells per area . Three independent 
experiments were made by triplicate and mean ± SEM were calculated for each 
experiment. Results were expressed as the percentage of stimulation in relation to 
control (cells without treatment). 
 
2.4. Colony Formation Assay 
Cells were cultured in a 6-well plate and after 48 h were exposed to various 
concentrations of P4 or ALLO (10-11, 10-8 y 10-5 M) for 72 h. Later, a suspension 
containing 100-1000 cells was plated in 6 well culture dishes for clonogenic assay. The 
cells were then incubated for 14 days at 37 °C with 5% CO2. The colonies were fixed 
by cold methanol, stained with 1% violet crystal in ethanol and then counted. Colonies 
with more than 30 cells were considered positive. Three independent experiments were 
made. The results were expressed as the mean of absorbance value of the triplicate 
samples ± SEM, and expressed as the percentage of clonogenic efficiency in relation 
to control (cells without treatment). 
 
2.5. Migration assay. 
IGROV-1 or SKOV-3 cells were seeded in 24-well plates at a density of 2x105 cells/well 
in RPMI with 5 % FBS. After 24 h, under subconfluency conditions (90%), cells were 
deprived of SFB by 24 h and they were treated with increasing concentrations of P4 or 
ALLO for 72 h in starvation conditions until finish assay. A wound of 4 μm wide was 
made on the monolayer, washed with PBS and photographed at regular intervals 
during 24 h. The area covered was calculated by comparing the area to time zero, with 
respect to the selected time interval. The covered area was integrated with image J 
software (NIH). Three independent experiments were made. Results were expressed 
as a percentage of migration in relation to the migration of cells without treatment 
considered as 100 % [27]. 
 
2.6. Statistical analysis 
Statistical analyses were performed using the GraphPad Prism 5 (Graphpad software 
Inc, San Diego, CA). Results are presented as mean ± SEM of at least three 




was analyzed by One-Way analysis of variance, Tukey's Multiple Comparison Test;  
p<0.05 was considered to be statistically significant. 
3. Results 
3.1. Effect of progesterone and allopregnanolone on human ovarian tumor cells 
proliferation assay. 
The effects of P4 and ALLO on proliferation of ovarian cancer cell lines IGROV-1 and 
SKOV-3 were analyzed using three diferent methods (MTS assay, trypan blue dye 
exclusion and Ki67 expression). Viability was evaluated using concentration-response 
curves that covered a range from 10-11 to 10-5 M for each steroid. As shown in Fig. 1A 
and 1B, P4 did not modify proliferation in any of the cell lines studied. The ALLO 
proliferacion curve has a similar patherns to a biphasic one. ALLO effect  was 
significantly different with respect to the control in a range of 10-8 to 10-5 M. The 
maximal effect concentration was 10-5 M, the highest concentration tested (44.5  13.5 
% proliferation respect to control; p<0.001) and in the lowest concentration tested (10-11 
M; p<0.001) , where the percentage of proliferation was increased by 38.6  16 % 
(p<0.001; ALLO vs control). 
 ALLO did not modify the proliferation of SKOV-3.  
Trypan blue assay showed an increase in living cells only after ALLO treatment on 
IGROV-1 cells, in a similar manner to MTS assay (data not shown). 





























































Fig. 1. Effect of progesterone or allopregnanolone on ovarian cancer cells 
proliferation. Concentration-response curves of progesterone or allopregnanolone on 
(A) IGROV-1 or (B) SKOV-3 cells proliferation. Values are expressed as mean ± SEM 
of three independent experiments performed in sixfold. **p<0.01; ***p<0.001 ALLO (M) 





Taking these results in consideration, the next step was to elucidate whether ALLO 
modulation on cell growth was associated with a modification on IGROV-1 cell 
proliferation and/or cell death. For that purpose, the expression of the proliferation 
marker Ki67 was assessed by immunostaining on treated cell monolayers. The number 
of Ki67 positive cells was augmented after ALLO treatment in IGROV-1 cells (Fig. 2A), 




Fig.2  Ki67 expression after allopregnanolone treatement on A) IGROV-1 and B) 
SKOV-3 cells. Graphs correspond to quantification of Ki67+ cells, relative to untreated 
cells as control. The images shown are representative, taken with a 4x magnification 
and correspond to the treatments indicated in the bar diagram. Values are expressed 
as mean ± SEM of three independent experiments performed in triplicate. *p<0.05; 
**p<0.01  ALLO (M) vs control (cells without treatment).  
 
3.2. Effect of allopregnanolone on human ovarian tumor cells apoptosis.  
To analyze the effect of ALLO on cell death, the expression of cleaved caspase 3 was 
studied. ALLO did not affect apoptosis with the tested concentrations (10-11M, 10-8 M y 









Fig.3: Cleaved caspase 3 expression after allopregnanolone treatment on A-D) 
IGROV-1 and E-H) SKOV-3 cells. The images shown are representative, taken with a 
4X magnification and correspond to  A, E) control and the treatments with  
allopregnanolone B,F) 10-11M, C-G) 10-8 M y D,H) 10-5 M. Values are expressed as 
mean ± SEM of three independent experiments performed in triplicate.  
 
3.3. Effect of progesterone and allopregnanolone on human ovarian tumor cells 
clonogenic capacity.  
To study long-term the effects of P4 and ALLO on IGROV-1 and SKOV-3 cells, colony 
formation assays were performed. Ovarian tumor cells were treated with increasing 
concentrations of P4 or ALLO for 72 h, and then, harvested and replate as a 
monocellular suspension. The cells were then allow to grow for fourteen days to 
investigate their colony formation ability. Whereas P4 did not modify the clonogenic 
capacity of IGROV-1 and SKOV-3 cells (Fig. 4A and 4B), Fig. 4C shows that ALLO 
induced a significant increase in the number of IGROV-1 cell colonies compared with 
the untreated cells. As expected, ALLO did not affect the clonogenic capacity on 




























































































































































Fig. 4. Effect of progesterone or allopregnanolone on (A and C) IGROV-1 and (B 
and D) SKOV-3 cells clonogenic capacity. Values are expressed as mean ± SEM of 
three independent experiments performed in triplicate. *p<0.05; **p<0.01; ALLO vs 
control (cells without treatment).  
 
3.4. Effect of progesterone and allopregnanolone actions on human ovarian 
tumor cells migration.  
A classical in vitro wound healing assay was used to measure the migration rate of 
ovarian tumor cells IGROV-1 and SKOV-3 after treatment with P4 and ALLO. Both 
steroids significantly increased the wound healing ability of IGROV-1 cells, in a  
concentration-dependent manner, compared with the untreated controls. The maximal 
effective concentration of P4 and ALLO were 10-11 M (the lower tested), that increased 
cell migration by a maximum 148  14% and 175  21% respectively (Fig 5A). None of 


































































Fig. 5. Concentration-response curves of progesterone or allopregnanolone on 
(A) IGROV-1 and (B) SKOV-3 cells migration. Values are mean ± SEM of three 
independent experiments performed in quadruplicate. **p<0.01; ***p<0.001  
progesterone/allopregnanolone (M) vs control (cells without treatment).  
 
4. DISCUSSION           
Tumor progression involves a several process that allow growth and metastasis 
formation. P4 presents a complex mechanism of action, which is not entirely clear, and 
that once metabolized produces active compounds that may also regulate physiological 
or pathological processes, such us ovarian cancer. In the current work, we investigated 
the effect of P4 and ALLO over some biological process related with tumor progression 
and present the first evidence that ALLO can regulate the progression of epithelial 
ovarian cancer.  
 
In this work it was evaluated: proliferation, apoptosis, clonogenic capacity and 
migration on human ovarian cancer cells. Under physiological conditions, the balance 
between proliferation and apoptosis remains closely regulated, thus ensuring the 
integrity of tissues and organs. Tumoral transformation interferes with the control of 
these processes, causing the uncontrolled division of malignant cells [28]. In this 
investigation, P4 did not affect proliferation but its metabolite, ALLO, stimulated 
IGROV-1 cells proliferation in a concentration-dependent manner. We found that in this 
cell line, ALLO produced an increase in viability at physiological (10-11 M) as well as at 
higher (10-5 M) concentrations (p<0.001) [29]. These results were corroborated by 




markers and, as expected, ALLO enhanced ki67 only on IGROV-1 cells. At the same 
time, ALLO did not change cleaved caspase 3 expression neither IGROV-1 nor SKOV-
3 cells. In accordance with our results, Zamora-Sanchez et al. (2017) [30] found that 
ALLO increases the number of tumor cells derived from glioblastoma by the regulation 
of genes involved in tumor progression. In turn, Shepelin et al. (2016) [31] 
demonstrated the existence of a relationship between melanoma progression and 
ALLO biosynthesis; this study was made with transcriptional data using computational 
tools. Moreover, in breast cancer cell lines, Xu et al. (2016) [32] showed that 
steroidogenesis stimulation increase the levels of ALLO and tumoral cell proliferation. 
Also, patients with breast cancer have high level of ALLO in cyst fluid [33]. Wiebe et al. 
(2000 and 2006) [12, 34] showed that an increase in 5α-pregnanes (which can serve 
as precursor to ALLO) promoted cell proliferation and detachment in breast cancer cell 
lines. These studies together with ours show the importance of considering the active 
metabolites of P4, in particular ALLO, as well as the regulation of their synthesis, in the 
progression of cancer. 
 
Peluso et al. (2009) [9] showed that P4 (10-6 o 10-9 M) did not change the apoptotic 
nuclei percentage on SKOV-3 cells. In vitro studies has shown that P4 has a dual 
effect, inhibiting or stimulating apoptosis. P4 induces apoptosis through classical 
progesterone receptors in several ovarian cancer cell lines [6, 7]. On the other hand, 
P4 protect ovarian cancer cells from the apoptotic effect produced by cisplatin, allowing 
the restoration to their proliferative and migratory capacity. These anti-apoptotic effect 
was mediated by the component 1 of the membrane P4 1/ 2 receptors (PGRMC1/2) 
through P3IK / AKT pathway [8, 9]. Prove that different action of this progestagens, 
could be a consequence of the differential expression of receptors or mediator signals.  
 
Furthermore, we analyzed cellular sensitivity of P4 or ALLO on the clonogenic capacity 
of both cell lines. Our results show that 72 h of P4 treatment did not modify the ability to 
form colonies in any of the cell lines studied. At the same time, McDonnel et al. (2003) 
[35] evidenced that P4 decreases membrane fluidity and inhibited colony formation 
(after 14 days treatment) in SKOV-3 cells. Even though there are evidence that P4 
might inhibit colony formation in SKOV-3 cells (35), it is known that the effects of 
progestagens varies according to the duration of treatment. ALLO increased 
clonogenic capacity only in IGROV-1 tumoral cells. This is consistent with the ability of 




steroids show, once again, the great complexity of its mechanism of action that not only 
depends on the concentration of these steroids but also on the time of its exposure. 
 
The metastatic process comprehends multiple steps, but migration has a critical role, 
allowing cells to reach blood vessels. Progestagens are involved in migration and 
invasion changes of breast cancer cells through alterations in the actin cytoskeleton 
[36]. In this work, P4 and ALLO enhanced IGROV-1 migration in a concentration-
dependent manner but had no effect on SKOV-3 migration. On IGROV-1, P4 and 
ALLO produced the maximum effect at the lowest concentration (10-11 M; p<0.001) that 
decreased until it became non-significant for higher concentrations. In accordance with 
our results, Fu et al. (2008) [36] observed that P4 stimulated cellular migration and 
invasion through a reorganization of the cytoskeleton, formation of pseudopodia and 
membrane extensions in a breast cancer cell line. Besides, Fu et al. (2010) [37] 
showed that P4 generates the phosphorylation of FA kinase (FAK) which increases 
migration of breast cancer cells. Interestingly, this enzyme has also been related with 
metastatic behavior in ovarian cancer [38]. It is important to highlight that it is the first 
report of ALLO regulating the tumor migration that could be involved in metastasis 
development of epithelial ovarian cancer.  
 
Until now, there were no reports of ALLO being involved in the regulation of tumor 
migration. Recently, this metabolite was found to be involved in physiological 
processes, development, maturation and regeneration of Schwann cells activating both 
proliferation and migration, through the modulation of the Src / FAF signaling pathway 
and actin rearrangements [39]. These antecedents cited above, including works where 
ALLO regulates tumor proliferation, clearly show that this metabolite has effects in itself 
and may affect tumor development. 
 
The contradictory results of P4 found in the literature may be caused by diverse 
factors. Many authors have shown time and concentration dependent effects, which 
are able to modulate apoptosis. Here, lower ALLO concentrations stimulated 
proliferation and migration; and higher ALLO concentrations only increased 
proliferation on IGROV-1. Also, the different effect observed on both cell lines could be 
due to the action of P4 or ALLO on different receptors. Further experiments are needed 
to identify the different molecular mechanism involved in P4 or ALLO response on 
IGROV-1 that  have not yet been characterized. Based on current evidence, ours and 




anti-tumor effects generated by P4 or its metabolites, and the effects of these steroids 
on different receptors. 
 
Our results contribute to clarify the action of P4 and its metabolite, ALLO, involved on 
ovarian cancer, which could lead to new alternatives for prevention, diagnosis or 
treatment. In a breast cancer in vivo e in vitro model, P4 stimulated tumorigenesis and 
this effect was blocked by finasteride (5α-reductase inhibitor) [40]. Moreover, 
dutasteride (another 5α-reductase inhibitor) was studied in clinical trials, with good 
effects on the regulation of ALLO levels and symptoms associated with menopausal 
syndrome [41]. We believe that therapeutic tools associated with the regulation of P4 
metabolism could be proposed by patients with ovarian cancer, such as blocking the 
enzyme 5α-reductase and, in turn, lowering ALLO levels; as well as blocking ALLO 
binding to its receptors or lowering its expression.  
 
5. Summary and conclusions 
P4 stimulated migration on IGROV-1 cells, and its metabolite, ALLO, enhanced 
proliferation, clonogenic capacity and migration in this cell line. Neither P4 nor ALLO 
modify progression on SKOV-3 cells.  
These findings are important to clarify the role of P4 in ovarian cancer and are the first 
evidence of ALLO, an active metabolite of P4, affecting tumor progression of cells 
derived from human ovarian epithelial tumors. These results may have therapeutic 
implications for patients which might benefit from the blockage of their action or the 
regulation of tumor steroidogenesis. 
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